Try our mobile app

Published: 2022-05-18 16:45:59 ET
<<<  go to CLX company page
0000021076 false 0000021076 2022-05-12 2022-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 13, 2022

THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)

___________________
 

Delaware

      

1-07151

     

31-0595760

(State or other jurisdiction of
incorporation)

(Commission File Number)

(I.R.S. Employer
Identification No.)

 

1221 Broadway, Oakland, California

   

94612-1888

(Address of principal executive offices)

(Zip code)

 
(510) 271-7000
(Registrant's telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]

Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)

 
[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Name of each exchange on which registered
Symbol(s)
Common Stock - $1.00 par value CLX New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company            ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.            ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On May 13, 2022, the Board of Directors (the “Board”) of The Clorox Company (the “Company”) elected Julia (Charter) Denman and Stephanie Plaines to the Board, each effective as of May 16, 2022. It is expected that both Ms. Denman and Ms. Plaines will be appointed to the Audit Committee at the Board meeting in September 2022. Each of Ms. Denman and Ms. Plaines will be provided with the Company’s standard non-employee director compensation and director indemnification agreement.

A press release announcing the election of Ms. Denman and Ms. Plaines is filed as Exhibit 99.1 and is incorporated herein in its entirety.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index below.

EXHIBIT INDEX

Exhibit       Description
     
99.1 Press Release dated May 18, 2022, of The Clorox Company
 
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CLOROX COMPANY
 
Date: May 18, 2022 By:          /s/ Angela Hilt
Angela Hilt
Senior Vice President – Chief Legal Officer